**Aligos Therapeutics Reports Financial Results and Operational Updates in Annual 10-K Filing**

Aligos Therapeutics, a clinical-stage biotechnology company, released its annual report on Form 10-K, detailing its financial performance and operational activities for the year ended December 31, 2025. The company, focused on developing novel therapeutics for liver diseases and viral infections, reported a net loss of $24.2 million for the year, compared to a net loss of $131.2 million for the year ended December 31, 2024. The decrease in net loss was primarily due to a change in the fair value of common warrants. The company's revenue consisted of $2.2 million in customer revenue, compared to $3.6 million for the year ended December 31, 2024, a decrease of $1.4 million, primarily due to the collaboration and license agreement with Amoytop, the collaboration portion of which ended in November 2025.

Research and development expenses totaled $69.5 million in 2025, a slight decrease from $70.3 million in 2024. This was primarily due to a decrease of $1.8 million in third-party expenses due to increased government funds received for the coronavirus program which offset related costs. There was also a decrease of $0.2 million in depreciation. Offsetting this were increases of $0.4 million in employee-related costs, $0.4 million in facility expenses, and $0.4 million in travel and recruiting expenses. General and administrative expenses decreased to $20.7 million from $22.8 million in the previous year, primarily due to a decrease of $2.1 million of third-party expenses primarily due to reduced legal and IP spend, and a decrease of $0.3 million in facility expenses. This was partially offset by an increase of $0.1 million in depreciation and $0.2 million in travel and recruiting costs. As of December 31, 2025, Aligos held $77.8 million in cash, cash equivalents, and short-term investments.

Key operational developments highlighted in the filing include the ongoing Phase 2 B-SUPREME study for pevifoscorvir sodium, a Capsid Assembly Modulator (CAM-E) for chronic HBV infection, with the first interim analysis expected in the first half of 2026 and topline data expected in 2027. The company also completed a Phase 2a study for ALG-055009, a THR-β agonist for MASH, demonstrating statistically significant reductions in liver fat. Furthermore, ALG-097558, a pan-coronavirus protease inhibitor, is currently in a Phase 2 study sponsored by the AGILE trial in the UK. As of December 31, 2025, the company employed 82 full-time employees, with 64 dedicated to research and development.

The filing also included forward-looking statements regarding the company's future financial performance, clinical trial plans, and regulatory strategies. Aligos anticipates that its existing cash resources will fund operations into the third quarter of 2026, necessitating additional financing to continue its development programs. The company acknowledged the inherent risks and uncertainties associated with drug development, including potential delays in clinical trials, regulatory approvals, and market acceptance of its drug candidates. The report of Aligos' independent registered public accounting firm included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapeutics for liver diseases and viral infections, including chronic hepatitis B virus (HBV), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. Its pipeline features small molecule and oligonucleotide drug candidates designed to improve treatment outcomes by targeting viral lifecycles and metabolic pathways. Aligos leverages proprietary platforms, in-licensing, and internal expertise to create potentially best-in-class therapies for large unmet medical needs.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.